Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim matches the FDA label boxed warning content in Section 5.1 regarding increased mortality risk in elderly patients with dementia-related psychosis treated with antipsychotic drugs.
Category Scores
Accurate Statements
The boxed-warning statement that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death.
FDA label Section 5.1 (Boxed Warning): “Increased Mortality — Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
Unsupported Statements
Contradictions
Important Omissions
The AI text provided does not include the label’s additional supporting details in Section 5.1 (e.g., placebo-controlled trial death incidence “3.5% vs 1.5%” and the note that olanzapine is not approved for dementia-related psychosis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim accurately reflects a boxed warning and does not introduce conflicting or unsupported safety information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The statement captures the core boxed-warning message but omits label supporting numeric incidence and the explicit “not approved for dementia-related psychosis” wording.
Suggested Improvement
Include the label’s accompanying Section 5.1 details (death incidence 3.5% vs 1.5% and the statement that olanzapine is not approved for dementia-related psychosis) when summarizing the boxed warning.